GMDA On Track, GNFT Soars, HTBX Sparkles, Eli Lilly's Neutralizing Antibody Therapies Get FDA Nod
(2) INDIANAPOLIS (dpa-AFX) - Today's Daily Dose brings you news about KalVista's hereditary angioedema trial results, Heat Biologics' encouraging data from its phase II trial of HS-110 in non-small cell lung cancer, Gamida's presentation of full efficacy and safety results of Omidubicel in patients with hematologic malignancies and Neovasc regaining Nasdaq compliance. Read on. 1. Gamida's Presentation At TCT Meetings Catches Eyes Shares of Gamida Cell Ltd. (GMDA) were up over 60% at $16 in extended trading Tuesday, following the presentation of full efficacy and safety results of the company...
Source: finanznachrichten.de